Product Reports Resources Pricing Login Book a demo

Alnylam Pharmaceuticals

Biotech & Life Sciences · Cambridge, United States · Founded 2002 · IPO 2004

Develops novel therapeutics-based RNAi and provides overviews of recent drug development programs

Valuation $25B
Revenue $5.58B
EBITDA $676M
Power Law Decacorn$10B+ valuation tier Thoroughbred$100M+ revenue
Featured in
News Atavistik Bio banks $160M to take novel blood disorder drugs into trials Mar 6, 2026

Investors

9 investors on Alnylam Pharmaceuticals's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 9 investors entered at this stage
Massachusetts Institute of Technology
Abingworth
Polaris Partners
ARCH Venture Partners
Atlas Venture
Cardinal Partners
Max Planck Society
Max Planck Innovation
Merck & Co.

Alnylam Pharmaceuticals mafia

Startups founded by Alnylam Pharmaceuticals alumni

Former Alnylam Pharmaceuticals employees who went on to start their own companies. Sorted by Dealroom signal score.

Scholar RockEst. 2012
Nagesh MahanthappaUnited States
Signal score93
AerskaEst. 2025
SMStuart MilsteinIreland
Signal score87
Imbria PharmaceuticalsEst. 2018
David-Alexandre "Da" GrosUnited States
Signal score85
Arpeggio BioEst. 2017
Tim ReadUnited States
Signal score85
General ProximityEst. 2019
ACArmand CognettaUnited States
Signal score74
Vesigen TherapeuticsEst. 2019
Robert MillmanUnited States
Signal score69
Blacksmith MedicinesEst. 2015
ZZZachary ZimmermanUnited States
Signal score63
Orbital TherapeuticsEst. 2022
John MaraganoreUnited States
Signal score62
OvaScienceEst. 2011
Christoph WestphalUnited States
Signal score61
Sirtris PharmaceuticalsEst. 2004
Paul SchimmelUnited States
Signal score60
Verseau TherapeuticsEst. 2017
Tatiana NovobrantsevaUnited States
Signal score59
480 BiomedicalEst. 2011
Robert LangerUnited States
Signal score57

Book a demo to explore the full alumni network →

Global footprint

Where Alnylam Pharmaceuticals has talent and traffic

Workforce by country
28 countries with
team presence
🇺🇸 United States79.2%
🇬🇧 United Kingdom5%
🇳🇱 Netherlands2.3%
🇨🇭 Switzerland2.3%
🇩🇪 Germany1.8%
Top 5 of 28 shown
Web traffic by country
100K monthly visits
across markets
🇺🇸 United States68.4%
🇬🇧 United Kingdom5.5%
🏳️ Korea3.9%
🏳️ Republic of3.6%
🇨🇦 Canada3.2%
Top 5 markets shown

Talent graph

The shape of Alnylam Pharmaceuticals's talent

Dealroom maps Alnylam Pharmaceuticals's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

8 standout operatorsDealroom-flagged across the org
12 AI specialistsincl. 3 core researchers
2,979 employees mappedperson by person
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Alnylam Pharmaceuticals's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$617M patent portfolio · 467 active families

Estimated portfolio value
$617M
2.4% of market cap · 6.9× larger than top peer Xenon Pharmaceuticals ($90M)
467 active patent families
Where Alnylam Pharmaceuticals innovates DiseaseDouble strandMolecular biologyBiochemistryCell biology

Where Alnylam Pharmaceuticals concentrates vs peers

Each axis is a top-10 topic across Alnylam Pharmaceuticals and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Alnylam Pharmaceuticals

An AI-synthesized read of the highest-engagement posts about Alnylam Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Alnylam Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles